Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense adjuvant chemotherapy with growth factor support for early stage breast cancer
ACTRN12606000030572Phase 2Recruiting
- Sponsor
- Amgen
- Start
- Jan 2006
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of doxorubicin, cyclophosphamide, paclitaxel, pegfilgrastim and darbepoetin alfa in breast cancer, sponsored by Amgen. Primary endpoint: Proportion of subjects with any chemotherapy cycle delay. Started Jan 2006; status: recruiting.
02
Drugs
doxorubicincyclophosphamidepaclitaxelpegfilgrastimdarbepoetin alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on ACTRN12606000030572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000030572.